Form 4: Bristol-Myers Squibb Grants Executive Equity

Bristol-Myers Squibb's President of RayzeBio Org. received significant performance-based equity awards.

Summary

• Benjamin Hickey, President of RayzeBio Org. at Bristol-Myers Squibb Company, reported the acquisition of derivative securities.
• The transaction involved 11,429 Market Share Units (MSUs) and 17,143 Performance Shares (PSUs) on March 10, 2026.
• Each Market Share Unit converts into common stock based on a payout factor, which is the greater of Total Return (80%-225%) and relative Total Shareholder Return (rTSR) Floor (0%-100%).
• MSUs cliff vest on March 10, 2029, contingent on Board certification of performance results.
• Each Performance Share Unit converts into one share of common stock upon distribution in the first quarter of 2029, also subject to Board certification of performance results.
• The reported price of these derivative securities was $0, indicating they were granted as compensation.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine and generally positive event, reflecting standard executive compensation practices designed to align management incentives with shareholder interests, without indicating any immediate operational or financial changes.

Positives

• The equity grants align the executive's long-term interests with those of shareholders through performance-based incentives.
• The structure of the Market Share Units and Performance Shares encourages the executive to drive both absolute and relative shareholder returns.

Negatives

• The value of the grants is entirely dependent on future company performance and stock price, introducing uncertainty for the executive.
• There is no immediate cash benefit to the executive from these grants.

Risks

• The payout for Market Share Units can be as low as 0% if the rTSR percentile rank is below the 50th percentile, or if Total Return performance does not meet the minimum 80% threshold.
• Performance Shares are subject to certification of performance results by the Board, meaning the full grant may not be realized.
• A decline in Bristol-Myers Squibb's stock price could significantly reduce the value of these equity awards.

Future Outlook

The future payout and conversion of these equity awards are contingent on Bristol-Myers Squibb's performance relative to specific metrics (Total Return and relative TSR) and subject to Board certification through early 2029.

Industry Context

StockSavvy.ai notes that performance-based equity grants, such as Market Share Units and Performance Shares, are a common component of executive compensation packages in the pharmaceutical and biotechnology industries. This practice aims to align executive incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The use of both absolute (Total Return) and relative (rTSR) performance metrics for equity awards is a standard practice among large-cap pharmaceutical companies, similar to compensation structures seen at peers like Pfizer, Merck, and Johnson & Johnson.
• The three-year cliff vesting period for MSUs and the Q1 2029 distribution for PSUs are typical long-term incentive structures designed to retain executives and reward sustained performance over several years, consistent with industry benchmarks.

Corporate Governance

Stakeholder Impact

• Shareholders: The performance-based nature of these awards aims to align the executive's financial incentives with shareholder value creation, potentially leading to improved long-term returns.
• Employees: This filing specifically details executive compensation and does not directly impact the broader employee base, though it reflects the company's overall compensation philosophy.

Next Steps

• Monitoring of Bristol-Myers Squibb's Total Return and relative Total Shareholder Return performance through March 2029.
• Board certification of performance results for both Market Share Units and Performance Shares.
• Vesting of Market Share Units on March 10, 2029.
• Distribution of common stock from Performance Shares in Q1 2029.

Key Dates

Keywords

Bristol-Myers Squibb, BMY, Form 4, Insider Transaction, Executive Compensation, Equity Grant, Market Share Units, Performance Shares, Benjamin Hickey, RayzeBio